Your browser doesn't support javascript.
loading
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Bonnefoi, H; Zaman, K; Debled, M; Fiche, M; Fournier, M; Nobahar, M; Pierga, J-Y; Koch, K M; Bartlett, J; Zimmer, A; Marreaud, S; Bogaerts, J; Cameron, D.
Affiliation
  • Bonnefoi H; Institut Bergonié, INSERM U916, Bordeaux, France. h.bonnefoi@bordeaux.unicancer.fr
Eur J Cancer ; 49(2): 281-9, 2013 Jan.
Article in En | MEDLINE | ID: mdl-22999386
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 / Inflammatory Breast Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2013 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 / Inflammatory Breast Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2013 Document type: Article Affiliation country: Country of publication: